Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2019 08:00 ET | Source: uniQure Inc.

uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B

~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported...
May 07, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting

~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
May 02, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 01, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 29, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress

~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity Sustained at up to 51% of Normal at 12 Weeks ~ Achieved IND...
April 15, 2019 12:15 ET | Source: uniQure Inc.

uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 08, 2019 07:00 ET | Source: uniQure Inc.

uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
March 29, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 29, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
March 01, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
February 28, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces 2018 Financial Results and Highlights Recent Company Progress

~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX Activity at up to 51% of...